Valuation Trading Multiples & Precedent Transactions: Small Molecule CDMO Companies
Valuation benchmarks for Small Molecule CDMO Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Small Molecule CDMO Companies Market Context & Valuation Drivers
Companies in this group are public contract development and manufacturing organizations focused on small‑molecule drug substances and related services. They generate revenue from fee‑for‑service research, CMC development, and multi‑year GMP supply agreements for APIs and intermediates, with select drug‑product and compounding capabilities. They are grouped as trading comparables given shared outsourcing models, regulatory track records, global manufacturing footprints, and exposure to innovator and generic pipelines.
Typical offerings span medicinal chemistry and discovery services, hit‑to‑lead optimization and screening, process and analytical development, and CMC documentation. Companies provide custom synthesis of intermediates, RSMs, and commercial APIs using chiral catalysis and continuous‑flow reactors, alongside peptide and highly potent small‑molecule capabilities. They scale from kilo‑lab to commercial GMP manufacturing, offer sterile compounding or fill‑finish in select cases, and maintain quality systems, regulatory filings, and supply‑chain management.
Primary customers include global pharma sponsors, specialty and mid‑cap biotechs, and generic drug manufacturers requiring outsourced chemistry and manufacturing. Valuation drivers center on revenue growth from pipeline wins, mix shift to commercial supply, capacity utilization and backlog visibility, and EBITDA margin expansion through scale and process yields. Regulatory compliance, quality track record, and multi‑year supply agreements underpin retention and pricing power.
2. Valuation Analysis: Public Trading Comps & Multiples for Small Molecule CDMO Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Small Molecule CDMO Companies sector
Comparable group 1: Small Molecule CDMO Companies
Fagron
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of pharmaceutical compounding solutions and personalized medicine services, utilizing advanced technology to meet the specific needs of healthcare providers and patients globally.
- Key Products:
- Sterile compounding: Production of individual sterile medications with rigorous quality control
- Custom formulations: Unique pharmaceutical preparations tailored to meet specific patient needs
- Fagron TrichoConcept: Multifunctional compounding vehicles for alopecia treatment with patented TrichoTech technology
- FagronLab Equipment: Advanced compounding tools and systems for pharmacies
- Fagron Formulary: Comprehensive range of customizable formulas for pharmacists and prescribers.
Pharmaron Beijing
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of comprehensive research, development, and manufacturing services for the life sciences industry, encompassing drug discovery, preclinical, clinical, and commercialization stages across small molecules, biologics, and cell and gene therapy (CGT) products.
- Key Products:
- Chemistry, Manufacturing & Controls: Comprehensive service capabilities throughout drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and CGT products
- Pharmaron Biologics: Drug product manufacturing, including liquid, lyophilized vials, and pre-filled syringes, offering flexible solutions
- Small Molecule Drug Product: Innovative and cost-effective solutions for drug development, covering a wide range of finished dosage forms including oral solid dosage forms
- Integrated Drug Discovery Services: Leads projects from hit identification to candidate selection
- Clinical Development: A broad spectrum of services for US clinical development processes.